Abstracts tagged "Biologic agents and spondylarthritis"

Abstract Number: 558 • 2019 ACR/ARP Annual Meeting
Frequency and Characteristics of Inflammatory Bowel Disease in Spondyloarthritis with Biological Therapy: Study of 270 Patients from the Same Center
Itziar Calvo-Zorrilla¹, María Luz García-Vivar ¹, Oihane Ibarguengoitia-Barrena ¹, David Montero-Seisdedos ¹, Lucía Vega-Alvarez ¹, Juan María Blanco-Madrigal ¹, Olaia Begoña Fernandez-Berrizbeitia ¹, María Esther Ruiz-Lucea ¹, Ignacio Torre-Salaberri ¹, Ana Rosa Intxaurbe-Pellejero ¹, Clara Eugenia Pérez-Velasquez ¹, Eduardo Cuende-Quintana ¹, Natalia Andrea Rivera-García ¹, María Jesus Allande-López-Linares ¹, Helena Ugarte-Zuazo ¹, Iñigo Gorostiza-Hormaeche ² and Eva Galíndez-Agirregoikoa ¹, ¹Rheumatology Unit, Basurto University Hospital, Bilbao, Spain, Bilbao, Spain, ²Investigation Unit, Basurto University Hospital, Bilbao, Spain, Bilbao, Spain
Background/Purpose: Inflammatory bowel disease (IBD) is an extra-articular manifestation that can appear in spondyloarthritis (SpA), as well as uveitis and psoriasis. Its prevalence is 5-10%,…
Abstract Number: 231 • 2017 ACR/ARHP Annual Meeting
Long Term Survival of Biological Agents in Patients with Axial Spondyloarthritis. the Impact of Sociodemographic Factors in Latin-America
Magdalena Cavalieri¹, Emilce E Schneeberger², Fernando Dal Pra¹, Rodrigo Garcia Salinas³, Hernán Maldonado Ficco⁴ and Gustavo Citera¹, ¹Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, ²Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, ³Section of Rheumatology, Hospital Italiano de La Plata, Buenos Aires, Argentina, La Plata, Argentina, ⁴Section of Rheumatology, Hospital San Antonio de Padua, Córdoba, Argentina, Córdoba, Argentina
Background/Purpose: The introduction of biological agents improved the prognosis of axial Spon-dyloarthritis (axSpA). The Lund Efficacy Index (LUNDEX) allows evaluation of both survival and efficacy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].